Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Krishnaswami

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Cardiovascular Surgery (London, England)|June 1, 1993
Tetralogy of Fallot: intracardiac repair in 840 subjectsS John, C John, V V Bashi, et al.
Clinical Pharmacology and Therapeutics|May 9, 2017
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-AnalysisT Checchio, S Ahadieh, P Gupta, et al.
The Journal of the Association of Physicians of India|July 1, 1970
Results of total correction of tetralogy of Fallot in twentyone casesS C Munsi, S John, T M Joseph, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 19, 2008
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokineticsE van Gurp, W Weimar, R Gaston, et al.
Journal of Clinical Pharmacology|January 5, 2002
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjectsH Möllmann, M Wagner, S Krishnaswami, et al.
Annals of the Rheumatic Diseases|November 16, 2014
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritisD L Boyle, K Soma, J Hodge, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 12, 2012
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 yearF Vincenti, H Tedesco Silva, S Busque, et al.
Clinical Pharmacology and Therapeutics|April 17, 2013
Model-based drug development: a rational approach to efficiently accelerate drug developmentP A Milligan, M J Brown, B Marchant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Cardiovascular Surgery (London, England)|June 1, 1993
Tetralogy of Fallot: intracardiac repair in 840 subjectsS John, C John, V V Bashi, et al.
Clinical Pharmacology and Therapeutics|May 9, 2017
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-AnalysisT Checchio, S Ahadieh, P Gupta, et al.
The Journal of the Association of Physicians of India|July 1, 1970
Results of total correction of tetralogy of Fallot in twentyone casesS C Munsi, S John, T M Joseph, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 19, 2008
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokineticsE van Gurp, W Weimar, R Gaston, et al.
Journal of Clinical Pharmacology|January 5, 2002
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjectsH Möllmann, M Wagner, S Krishnaswami, et al.
Annals of the Rheumatic Diseases|November 16, 2014
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritisD L Boyle, K Soma, J Hodge, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 12, 2012
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 yearF Vincenti, H Tedesco Silva, S Busque, et al.
Clinical Pharmacology and Therapeutics|April 17, 2013
Model-based drug development: a rational approach to efficiently accelerate drug developmentP A Milligan, M J Brown, B Marchant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Pageof 16